{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:43:43Z","timestamp":1793209423590,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an\u00a0expected overall survival (OS) of 3\u20135\u00a0months. Eltanexor is an investigational oral selective inhibitor of nuclear export with low central nervous system penetrance and an acceptable tolerability profile. Preclinical studies suggest that myeloid malignancies are sensitive to nuclear export inhibition. Eltanexor exhibited efficacy in hematologic models, supporting exploration in a clinical trial. This phase 1\/2 study (NCT02649790) assessed single-agent activity of eltanexor in patients with higher-risk MDS and 5\u201319% myeloblasts. Two starting doses of eltanexor were evaluated: 20\u00a0mg (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915), 10\u00a0mg (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095), both administered on days 1\u20135 each week of a 28-day cycle. Twenty patients with primary HMA-refractory MDS, with a median age of 77\u00a0years (range 62\u201389), and a median of\u00a0two prior treatment regimens (range 1\u20134) were enrolled. Of these, 15 were evaluated for efficacy and 20 for safety. The overall response rate (ORR) was 53.3%, with seven patients (46.7%) achieving marrow complete remission (mCR) and one additional patient achieving hematologic improvement (HI). In the 10\u00a0mg group, three\u00a0patients (60%) reached mCR and two (40%) stable disease (SD), while for 20\u00a0mg, four patients (40%) had mCR and two (20%) SD. A total of three patients (20%) had HI and became transfusion independent\u2009\u2265\u20098\u00a0weeks. Median OS for the efficacy-evaluable patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915) was 9.86\u00a0months (7.98, NE). Overall, the most frequently reported treatment-related adverse events were nausea (45%), diarrhea (35%), decreased appetite (35%), fatigue and neutropenia (both 30%). Single-agent oral eltanexor was active, safe, and well tolerated in patients with higher-risk, primary HMA-refractory MDS.\n                  <\/jats:p>","DOI":"10.1186\/s13045-022-01319-y","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T10:25:14Z","timestamp":1659522314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents"],"prefix":"10.1186","volume":"15","author":[{"given":"Sangmin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Knupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Chamoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Baloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Kauffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"1319_CR1","doi-asserted-by":"publisher","first-page":"204062072095500","DOI":"10.1177\/2040620720955006","volume":"11","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Carraway H, Prebet T. Emerging treatment options for patients with high-risk myelodysplastic syndrome. Ther Adv Hematol. 2020;11:204062072095500.","journal-title":"Ther Adv Hematol"},{"key":"1319_CR2","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JPJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794\u2013803.","journal-title":"Cancer"},{"key":"1319_CR3","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M L\u00fcbbert","year":"2011","unstructured":"L\u00fcbbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the european organisation for rese. J Clin Oncol. 2011;29:1987\u201396.","journal-title":"J Clin Oncol"},{"key":"1319_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3324\/haematol.2009.010611","volume":"95","author":"R Gurion","year":"2010","unstructured":"Gurion R, Vidal L, Gafter-Gvili A, Yeshurun YB, Raanani P, Shpilberg O. 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis. Haematologica. 2010;95:303\u201310.","journal-title":"Haematologica"},{"key":"1319_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1182\/blood.V110.11.817.817","volume":"110","author":"P Fenaux","year":"2007","unstructured":"Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood. 2007;110:817\u2013817.","journal-title":"Blood"},{"key":"1319_CR6","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Pr\u00e9bet","year":"2011","unstructured":"Pr\u00e9bet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322\u20137.","journal-title":"J Clin Oncol"},{"key":"1319_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/HS9.0000000000000219","volume":"3","author":"L Ad\u00e8s","year":"2019","unstructured":"Ad\u00e8s L. High-risk MDS after HMAs. HemaSphere. 2019;3:138\u201340.","journal-title":"HemaSphere"},{"key":"1319_CR8","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/leu.2016.136","volume":"30","author":"ZA Hing","year":"2016","unstructured":"Hing ZA, Fung HYJ, Ranganathan P, et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia. 2016;30:2364\u201372.","journal-title":"Leukemia"},{"key":"1319_CR9","unstructured":"XPOVIO highlights of prescribing information. www.fda.gov\/medwatch. (Accessed Feb 1, 2021)."},{"key":"1319_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","volume":"17","author":"G Garcia-Manero","year":"2016","unstructured":"Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:496\u2013508.","journal-title":"Lancet Oncol"},{"key":"1319_CR11","unstructured":"Astex Pharmaceuticals Inc. Astex and Otsuka announce results of phase 3 ASTRAL-2 and ASTRAL-3 studies of guadecitabine (SGI-110) in patients with previously treated acute myeloid leukemia (AML) and myelodysplastic syndromes or chronic myelomonocytic leukemia (MDS\/CMML) \u2013 Astex. 2020. https:\/\/astx.com\/astex-and-otsuka-announce-results-of-phase-3-astral-2-and-astral-3-studies-of-guadecitabine-sgi-110-in-patients-with-previously-treated-acute-myeloid-leukemia-aml-and-myelodysplastic-syndromes-or\/ (Accessed Jan 27, 2022)."},{"key":"1319_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/leu.2016.145","volume":"31","author":"J Etchin","year":"2017","unstructured":"Etchin J, Berezovskaya A, Conway AS, et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2017;31:143\u201350.","journal-title":"Leukemia"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01319-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01319-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01319-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T10:25:43Z","timestamp":1659522343000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01319-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1319"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01319-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"19 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients prior to enrollment by the ethics committee at each respective institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SL reports consultancy for Abbvie, AstraZeneca, BMS, Innate, Pin Therapeutics, and employment at Janssen Research and Development. SM reports research funding from Incyte, Karyopharm, and Taiho. JK, KC, AD, FY, and EB are all current employees of Karyopharm Therapeutics Inc. MK and SS are stockholders of Karyopharm Therapeutics Inc. JS, MK, and SS are former employees of Karyopharm Therapeutics Inc. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}